ALLMedicine™ Cholinergic Urticaria Center
Research & Reviews 47 results
https://clinicaltrials.gov/ct2/show/NCT03749148
Jan 31st, 2023 - Treatment with Dupilumab has been shown to reduce clinically significant exacerbations and to improve skin symptom control as well as quality of life in moderate to severe atopic dermatitis patients and in moderate to severe asthma patients. It ha...
https://clinicaltrials.gov/ct2/show/NCT04548869
Dec 21st, 2022 - This study is an open label Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria who remain symptomati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637282
The American Journal of Medicine; Ishizuka K, Ohira Y
Nov 10th, 2022 - Cholinergic urticaria after COVID-19 infection.|2022|Ishizuka K,Ohira Y,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476404
American Journal of Clinical Dermatology; Fukunaga A, Oda Y et. al.
Sep 16th, 2022 - Cholinergic urticaria (CholU) is a subtype of chronic inducible urticaria with a chief complaint of itching and/or stinging, painful papular wheals that develop simultaneously with sweating. This review specifically focuses on several subtypes of ...
https://clinicaltrials.gov/ct2/show/NCT04853992
Sep 2nd, 2022 - This is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted in Germany at 3-6 sites. Subjects will be randomised to one of two treatment sequences (A and B). Each treatment period will last 7 days with a wash-out p...
Clinicaltrials.gov 4 results
https://clinicaltrials.gov/ct2/show/NCT03749148
Jan 31st, 2023 - Treatment with Dupilumab has been shown to reduce clinically significant exacerbations and to improve skin symptom control as well as quality of life in moderate to severe atopic dermatitis patients and in moderate to severe asthma patients. It ha...
https://clinicaltrials.gov/ct2/show/NCT04548869
Dec 21st, 2022 - This study is an open label Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria who remain symptomati...
https://clinicaltrials.gov/ct2/show/NCT04853992
Sep 2nd, 2022 - This is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted in Germany at 3-6 sites. Subjects will be randomised to one of two treatment sequences (A and B). Each treatment period will last 7 days with a wash-out p...
https://clinicaltrials.gov/ct2/show/NCT02012387
Feb 12th, 2019 - Physical urticarias, such as delayed pressure, cholinergic, dermatographism and cold urticaria, are highly disabling conditions[1]. Cholinergic urticaria occurs due to an active (e.g. exercise) or passive (e.g. hot bath) increase in core body temp...
News 2 results
https://reference.medscape.com/viewarticle/881373_4
Jun 13th, 2017 - The differential diagnosis for EIA includes cholinergic urticaria, idiopathic cold urticaria, mastocytosis, cardiovascular disorders, food allergy exacerbated by exercise, and angioedema. Cholinergic urticaria is a form of physical urticaria that ...
https://www.mdedge.com/dermatology/article/98678/urticaria/cholinergic-urticaria-anaphylaxis-hazardous-duty-deployed-us
Kent S. Handfield, MD, MPH, Christopher K. Dolan, MD et. al.
Apr 10th, 2015 - Cholinergic urticaria (CU) is a condition that primarily affects young adults. It can severely limit their activity levels and therefore job performance.